Key result
The monoclonal antibody CYFN1006-1, isolated from a donor exposed only to ancestral SARS-CoV-2, exhibited robust cross-neutralization against variants including KP.2, KP.3, and XEC (IC50 ~1-5 ng/mL) and significantly reduced JN.1 viral replication in a hamster model.
Why the study?
The emergence of various SARS-CoV-2 variants challenges antibody therapeutics, emphasizing the need for more potent and broadly neutralizing antibodies.
Potent, broadly neutralizing antibodies against recent SARS-CoV-2 variants can be isolated from individuals exposed only to the ancestral virus, offering potential therapeutic candidates.
Hypothesis-generating for broad mAbs from ancestral exposure; human trials required before any clinical consideration.
The emergence of various SARS-CoV-2 variants presents challenges for antibody therapeutics, emphasizing the need for more potent and broadly neutralizing antibodies. Here, we employed an unbiased screening approach and successfully isolated two antibodies from individuals with only exposure to ancestral SARS-CoV-2. One of these antibodies, CYFN1006-1, exhibited robust cross-neutralization against a spectrum of SARS-CoV-2 variants, including the latest KP.2, KP.3 and XEC, with consistent IC50 values ranging from ~1 to 5 ng/mL. It also displayed broad neutralization activity against SARS-CoV and related sarbecoviruses. Structural analysis revealed that these antibodies target shared hotspot but mutation-resistant epitopes, with their Fabs locking receptor binding domains (RBDs) in the “down” conformation through interactions with adjacent Fabs and RBDs, and cross-linking Spike trimers into di-trimers. In vivo studies conducted in a JN.1-infected hamster model validated the protective efficacy of CYFN1006-1. These findings suggest that antibodies with cross-neutralization activities can be identified from individuals with exclusively ancestral virus exposure. Functional and structural studies of two potent antibodies isolated from individuals exposed only to ancestral SARS-CoV-2, demonstrating broad neutralization against the latest SARS-CoV-2 variants and related sarbecoviruses.
No takes yet. Share an insight, caveat, or question.
Lei et al. (2025) studied SARS-CoV-2 infection (n=3). CYFN1006-1 monoclonal antibody vs. PBS was evaluated on In vitro viral neutralization (IC50) and in vivo reduction of viral replication. The monoclonal antibody CYFN1006-1, isolated from a donor exposed only to ancestral SARS-CoV-2, exhibited robust cross-neutralization against variants including KP.2, KP.3, and XEC (IC50 ~1-5 ng/mL) and significantly reduced JN.1 viral replication in a hamster model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: